Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2
Status:
Completed
Trial end date:
2021-05-15
Target enrollment:
Participant gender:
Summary
Summary Currently, the COVID-19 pandemic has overtaken health systems worldwide, exceeding
the capacity of intensive care units. In addition to this, countries such as the United
States have reported a decrease in the supplies of drugs such as Propofol and Midazolam
(traditionally used as sedatives in patients with invasive mechanical ventilation), so in the
absence until now of a specific treatment against SARS-COV-2 virus, improving the support
strategies in patients in the severe spectrum of the disease Acute Respiratory Distress
Syndrome (ARDS) is a priority.
Given the global state of emergency due to COVID-19, the use of sevoflurane has the potential
to mitigate the shortages of sedative drugs, promote the recovery of patients with ARDS, and
potentially reduce mortality.
A study will be conducted to evaluate the effect of sevoflurane as inhalation sedation in
patients with ARDS secondary to SARS-COV2 compared to the standard. The primary objective of
the study is to assess the difference in oxygenation, for which the calculation of the
partial pressure of arterial oxygen to fractional inspired oxygen concentration ratio (PaO2 /
FiO2) will be used at 24 and 48 hours. Also, the effect of the possible attenuation or
inhibition of hypoxic pulmonary vasoconstriction will be evaluated by hemodynamic monitoring
with a pulmonary artery catheter and transthoracic echocardiography and its possible effect
on the right ventricle.
Outcome: we expect an improvement in oxygenation and consequently a reduction in the days of
invasive mechanical ventilation, stay in the intensive care unit (ICU) and hospital. In
addition to evaluating its possible anti-inflammatory effect and probably establishing a safe
and effective alternative and possibly with greater benefits compared to standard intravenous
sedation.